Tahereh Sabaghian, Minoo Heidari Almasi, Farzaneh Futuhi, M. Shabani, Azam Erfanifar, S. A. Ebadi
{"title":"ACEI/ARB对新冠肺炎住院患者预后的影响","authors":"Tahereh Sabaghian, Minoo Heidari Almasi, Farzaneh Futuhi, M. Shabani, Azam Erfanifar, S. A. Ebadi","doi":"10.5812/numonthly-121819","DOIUrl":null,"url":null,"abstract":": Considering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regression model, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients\",\"authors\":\"Tahereh Sabaghian, Minoo Heidari Almasi, Farzaneh Futuhi, M. Shabani, Azam Erfanifar, S. A. Ebadi\",\"doi\":\"10.5812/numonthly-121819\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Considering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regression model, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.\",\"PeriodicalId\":19466,\"journal\":{\"name\":\"Nephro-urology Monthly\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephro-urology Monthly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/numonthly-121819\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephro-urology Monthly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/numonthly-121819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
考虑到血管紧张素II型受体阻滞剂(ARB)和血管紧张素转换酶抑制剂(ACEI)对COVID-19患者预后的影响有不同的报道,我们旨在对138例高血压患者(81例使用ACEI/ARB)进行回顾性研究,通过比较ACEI/ARB和非ACEI/ARB患者的预后。多因素校正cox回归模型在考虑其他变量影响的情况下显示,年龄增加(HR = 1.04, 95% CI = 1.01 ~ 1.07, P =0.003)和非ACEI/ARB使用者(HR = 2.12, 95% CI = 1.12 ~ 4.13, P = 0.021)与随访1周左右住院死亡风险增加相关。总之,我们发现ACEI/ARB使用者的住院死亡率较低,表明这些治疗对患者预后有积极影响。
The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients
: Considering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regression model, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.